COMBINED MIRTAZAPINE and SSRI TREATMENT of PTSD: A PLACEBO-CONTROLLED TRIAL

Depression and Anxiety

Volumn 32, Issue 8, 2015, Pages 570-579

  Schneier, Franklin R ^a,b   Campeas, Raphael ^a,b   Carcamo, Jaime ^c   Glass, Andrew ^d   Lewis Fernandez, Roberto ^a,b   Neria, Yuval ^a,b   Sanchez Lacay, Arturo ^a,b   Vermes, Donna ^a   Wall, Melanie M ^a,b,d  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c Hispanic Family Mental Health Center   (United States)

^d Department of Medicine   (United States)

Author keywords

antidepressants; anxiety; combined treatment; norepinephrine; posttraumatic stress disorder; psychopharmacology; randomized clinical trial; serotonin

Indexed keywords

MIRTAZAPINE; PLACEBO; SERTRALINE; MIANSERIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; APATHY; ARTICLE; BEDTIME DOSAGE; BLURRED VISION; CLINICAL ARTICLE; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION DISORDER; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HEARTBURN; HUMAN; HYPERHIDROSIS; INCREASED APPETITE; INSOMNIA; LIBIDO DISORDER; MALE; NAUSEA; NERVOUSNESS; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SKIN BRUISING; SKIN DISEASE; SLEEP QUALITY; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY DYSFUNCTION; VOMITING; WEIGHT GAIN; XEROSTOMIA; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; MIDDLE AGED; OUTCOME ASSESSMENT; STRESS DISORDERS, POST-TRAUMATIC; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STRESS DISORDERS, POST-TRAUMATIC; YOUNG ADULT;

EID: 84937925714     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22384     Document Type: Article

References (43)

1. Kessler RC, Sonnega A, Bromet E, et al., Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52: 1048-1060.
2. Breslau N., The epidemiology of posttraumatic stress disorder: what is the extent of the problem? J. Clin Psychiatry 2001; 62: 16-22
3. Neria Y, Nandi A, Galea S,. Post-traumatic stress disorder following disasters: a systematic review. Psychol Med 2008; 38: 467-480.
4. Roberts AL, Gilman SE, Breslau J, et al., Race/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States. Psychol Med 2011; 41: 71-83.
5. Kessler RC., Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry 2000; 61: 4-12.
6. Gradus JL, Qin P, Lincoln AK, et al., 2010. Posttraumatic stress disorder and completed suicide. Am J Epidemiol 171: 721-727.
7. McFarlane AC., The longitudinal course of posttraumatic morbidity. The range of outcomes and their predictors. J Nerv Ment Dis 1988; 176: 30-39.
8. Institute of Medicine, Committee on Treatment of Posttraumatic Stress Disorder, Board on Population Health and Public Health Practice. Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence. 2008. Available at: http://www.nap.edu/catalog/11955.html.
9. Davidson JRT., Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. Psychopharmacology 2004; 19: 85-87.
10. Tucker P, Potter-Kimball R, Wyatt DB, et al., Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Gen Psychopharmacol 2003; 37: 135-149.
11. Meltzer-Brody S, Connor KM, Churchill E, Davidson JR,. Symptom-specific effects of fluoxetine in post-traumatic stress disorder. Int Clin Psychopharmacol 2000; 15: 227-231.
12. Brady K, Pearlstein T, Asnis GM, et al., Efficacy and safety of sertraline treatment of posttraumatic stress disorder. J Am Med Assoc 2000; 283: 1837-1844.
13. Davidson J, Pearlstein T, Londborg P, et al., Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 1974-1981.
14. Stein DJ, Ipser JC, Seedat S,. Pharmacotherapy for posttraumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006; 25 (1): CD002795.
15. Londborg PD, Hegel MT, Goldstein S, et al., Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 2001; 62: 325-331.
16. Marshall RD, Lewis-Fernandez R, Blanco C, et al., A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety 2007; 24: 77-84.
17. de Boer T., The pharmacological profile of mirtazapine. J Clin Psychiatry 1995; 57 (Suppl. 4): 19-26
18. Besson A, Haddjeri N, Blier P, de Montigny C,. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 2000; 10: 177-188.
19. Blier P, Gobbi G, Turcotte JE, et al., Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009; 19: 457-465.
20. Blier P, Ward HE, Tremblay P, et al., Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281-288.
21. Carpenter LL, Yasmin S, Price LH,. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002; 51: 183-188.
22. Pallanti S, Quercioli L, Bruscoli M,. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004; 65: 1394-1399.
23. Rush AJ, Trivedi MH, Stewart JW, et al., Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168: 689-701.
24. Lewis JD., Mirtazapine for PTSD nightmares (letter). Am J Psychiatry 2002; 159: 1948-1949.
25. Alfaro, CL, Lam YW, Simpson J, Ereshefsky L,. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000; 40: 58-66.
26. Weathers FW, Keane TM, Davidson JRT,. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety 2001; 13: 132-156.
27. First MB, Spitzer RL, Gibbon M, et al., User's Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders. Washington, D C: American Psychiatric Press; 1997.
28. Guy W., ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76-338). Rockville, MD; 1976.
29. Hamilton M., A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
30. McGahuey CA, Gelenberg AJ, Laukes CA, et al., The Arizona sexual experience scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26: 25-40.
31. Endicott J, Nee J, Harrison W, et al., Quality of life, enjoyment, and satisfaction questionnaire: a new measure. Psychopharm Bull 1993; 29: 321-326.
32. Foa E,. The Post Traumatic Diagnostic Scale Manual. Minneapolis, MN; NCS, 1995.
33. Buysse DJ, Reynolds CF, 3rd, Monk TH, et al., The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
34. Germain A, Hall M, Krakow B, et al., A brief sleep scale for posttraumatic stress disorder: Pittsburgh Sleep Quality Index addendum for PTSD. J Anxiety Disord 2005; 19: 233-244.
35. Ware JE, Snow KK, Kosinski M, et al., SF-36 Health Survey: Manual and Interpretation Guide. Boston, M A: Health Institute, New England Medical Center; 1993.
36. Fitzmaurice GM, Laird NM, Ware JH,. Applied Longitudinal Analysis. Hoboken, NJ: Wiley; 2004.
37. Ehlers A, Hackmann A, Michael T,. Intrusive re-experiencing in post-traumatic stress disorder: phenomenology, theory, and therapy. Memory 2004; 12: 403-415.
38. Stander VA, Thomsen CJ, Highfill-McRoy RM,. Etiology of depression comorbidity in combat-related PTSD: a review of the literature. Clin Psychol Rev 2014; 34: 87-98.
39. Gentes EL, Dennis PA, Kimbrel NA, et al., DSM-5 posttraumatic stress disorder: factor structure and rates of diagnosis. J Psychiatr Res. 2014; 59: 60-67.
40. Roy-Byrne P, Berliner L, Russo J, et al., Treatment preferences and determinants in victims of sexual and physical assault. J Nerv Ment Dis 2003; 191: 161-165.
41. Zoellner LA, Feeny NC, Cochran B, Pruitt L,. Treatment choice for PTSD. Behav Res Ther 2003; 41: 879-886.
42. Ten Have TR, Normand SL, Marcus SM, et al., Intent-to-treat vs. non-intent-to-treat analyses under treatment non-adherence in mental health randomized trials. Psychiatr Ann 2008; 38: 772-783.
43. Heritier SR, Gebski VJ, Keech AC,. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust 2003; 179: 438-440.